VITIELLO, FRANCESCO
 Distribuzione geografica
Continente #
NA - Nord America 1.114
AS - Asia 671
EU - Europa 662
SA - Sud America 99
AF - Africa 11
OC - Oceania 1
Totale 2.558
Nazione #
US - Stati Uniti d'America 1.083
RU - Federazione Russa 420
SG - Singapore 274
CN - Cina 164
IT - Italia 108
BR - Brasile 80
BD - Bangladesh 61
HK - Hong Kong 52
VN - Vietnam 50
DE - Germania 30
FR - Francia 28
GB - Regno Unito 23
CA - Canada 19
IN - India 19
JP - Giappone 15
NL - Olanda 12
AR - Argentina 9
PL - Polonia 9
MX - Messico 8
ES - Italia 6
FI - Finlandia 6
SE - Svezia 6
SA - Arabia Saudita 5
ID - Indonesia 4
LT - Lituania 4
TR - Turchia 4
ZA - Sudafrica 4
AE - Emirati Arabi Uniti 3
AT - Austria 3
IQ - Iraq 3
MY - Malesia 3
NP - Nepal 3
PK - Pakistan 3
BE - Belgio 2
BO - Bolivia 2
CO - Colombia 2
EG - Egitto 2
JM - Giamaica 2
MA - Marocco 2
TW - Taiwan 2
VE - Venezuela 2
AL - Albania 1
AU - Australia 1
BA - Bosnia-Erzegovina 1
CG - Congo 1
EC - Ecuador 1
HN - Honduras 1
IL - Israele 1
KE - Kenya 1
KG - Kirghizistan 1
LK - Sri Lanka 1
MD - Moldavia 1
MV - Maldive 1
PE - Perù 1
PH - Filippine 1
PY - Paraguay 1
RS - Serbia 1
SI - Slovenia 1
SV - El Salvador 1
TH - Thailandia 1
TN - Tunisia 1
UY - Uruguay 1
Totale 2.558
Città #
Dallas 734
Singapore 185
Moscow 75
Ashburn 62
Hong Kong 50
Beijing 43
San Jose 42
New York 34
Los Angeles 25
Ho Chi Minh City 18
Santa Clara 18
Munich 17
Orem 15
Lauterbourg 14
Hanoi 13
Milan 12
Rome 12
São Paulo 12
Tokyo 12
Montreal 9
Hefei 8
London 8
Poplar 8
Manchester 7
Naples 7
Warsaw 7
Bacoli 6
Denver 6
Frankfurt am Main 6
Guangzhou 6
Phoenix 6
Secaucus 6
Shanghai 6
Stockholm 6
Atlanta 5
Brooklyn 5
Cesano Boscone 5
Chennai 5
North Bergen 5
Bari 4
Chicago 4
Monza 4
Mumbai 4
Newark 4
Riyadh 4
Tianjin 4
Toronto 4
Boardman 3
Boston 3
Da Nang 3
Dhaka 3
Helsinki 3
Houston 3
Johannesburg 3
Mexico City 3
Nanning 3
Porto Alegre 3
Querétaro 3
Shenzhen 3
Agadir 2
Amsterdam 2
Ankara 2
Belo Horizonte 2
Biên Hòa 2
Brussels 2
Buffalo 2
Charlotte 2
Chengdu 2
Cleveland 2
Colombo 2
Council Bluffs 2
Duque de Caxias 2
Forcalquier 2
Formosa 2
Fortaleza 2
Guarulhos 2
Helena 2
Ipoh 2
Jinhua 2
Kathmandu 2
Lappeenranta 2
Marseille 2
Milwaukee 2
New Delhi 2
Nuremberg 2
Padua 2
Pelotas 2
Pescara 2
Phủ Lý 2
Pittsburgh 2
San Francisco 2
Santa Fe 2
São José dos Campos 2
Trieste 2
Vignola 2
Wroclaw 2
Adel 1
Alexandria 1
Almirante Tamandaré 1
Alto Paraguai 1
Totale 1.666
Nome #
Adverse Events as Potential Predictive Factors of Activity in Patients with Advanced HCC Treated with Atezolizumab Plus Bevacizumab 430
Disease Etiology Impact on Outcomes of Hepatocellular Carcinoma Patients Treated with Atezolizumab plus Bevacizumab: A Real-World, Multicenter Study 420
Safety and Efficacy of Lenvatinib in Very Old Patients with Unresectable Hepatocellular Carcinoma 136
Lenvatinib versus Sorafenib Second-Line Therapy in Patients with Hepatocellular Carcinoma Progressed to Atezolizumab plus Bevacizumab: A Retrospective Real-World Study 129
Impact of body mass index on the prognosis of unresectable HCC patients receiving first-line Lenvatinib or atezolizumab plus bevacizumab 129
Developing targeted therapeutics for hepatocellular carcinoma: a critical assessment of promising phase II agents 120
Different Genomic Clusters Impact on Responses in Advanced Biliary Tract Cancer Treated with Cisplatin Plus Gemcitabine Plus Durvalumab 110
Germline testing and genetic counseling in biliary tract cancer: an operative proposal to improve the state of art 107
Factors associated with reaching maintenance therapy in patients with advanced biliary tract cancer treated with durvalumab: Real-world results from a multicenter and multinational study 105
Intermediate hepatocellular carcinoma: new horizons and prospects for our patients 104
Atezolizumab plus bevacizumab versus Lenvatinib for patients with Barcelona clinic liver cancer stage B (BCLC-B) hepatocellular carcinoma (HCC): A real-world population 103
HER2 Pathway in Biliary Tract Cancer: A Snapshot of the Current Understanding and Future Directions 98
α-FAtE: A new predictive score of response to atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma 90
Impact of metformin, statin, aspirin and insulin on the prognosis of uHCC patients receiving first line Lenvatinib or Atezolizumab plus Bevacizumab 83
Survival Outcomes of Durvalumab in Combination with Cisplatin and Gemcitabine in Advanced Biliary Tract Cancer: Real-World Results from a Single Italian Institution 83
Comparative Effectiveness of Atezolizumab Plus Bevacizumab Versus Tremelimumab Plus Durvalumab in Patients with Hepatocellular Carcinoma (HCC) in a Real-World Setting 74
Anti-HER2 therapies in biliary tract cancers: A meta-analysis on disease location, HER2 status, and survival outcomes 73
Past, present, and future of FGFR inhibitors in cholangiocarcinoma: from biological mechanisms to clinical applications 73
Impact of Antibiotic Therapy in Patients with Cholangiocarcinoma Treated with Chemoimmunotherapy 70
Early bevacizumab dose and time modifications may affect efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma treatment 69
null 7
Immunotherapy in small bowel adenocarcinoma: a potential role? 4
Comprehensive genetic analysis in biliary tract cancer: a prospective single-center experience 2
Unleashing precision: A review of targeted approaches in pleural mesothelioma 2
Totale 2.621
Categoria #
all - tutte 5.529
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 5.529


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2023/202412 0 0 0 0 0 0 0 0 0 1 6 5
2024/2025117 6 0 0 3 8 10 11 16 5 5 10 43
2025/20262.492 114 390 489 231 176 79 105 159 406 92 149 102
Totale 2.621